Louisiana State Employees Retirement System Buys Shares of 21,000 Prestige Consumer Healthcare Inc. $PBH

Louisiana State Employees Retirement System bought a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 1st quarter, Holdings Channel reports. The firm bought 21,000 shares of the company’s stock, valued at approximately $1,245,000.

Several other hedge funds have also made changes to their positions in PBH. UMB Bank n.a. increased its holdings in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new position in Prestige Consumer Healthcare in the fourth quarter valued at approximately $29,000. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares during the last quarter. Geneos Wealth Management Inc. grew its position in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the period. Finally, Torren Management LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter worth approximately $35,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PBH shares. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $49.38 on Friday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $80.69. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57. The company has a 50 day moving average price of $49.36 and a 200 day moving average price of $58.27. The stock has a market capitalization of $2.34 billion, a P/E ratio of 12.63, a PEG ratio of 1.59 and a beta of 0.35.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. During the same period in the previous year, the firm posted $1.32 earnings per share. The company’s quarterly revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is owned by company insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).